Use of a Autologous MiniTC MFAT Injection to Improve Shoulder Pain and Function Among Patients with Osteoarthritis
Dr. Ariana DeMers
DO, Oklahoma State University College Osteopathic Medicine
Dr. DeMers is a board-certified, fellowship-trained orthopedic surgeon. In her practice, she sees everyone from kids with playground injuries to high school and college athletes. Her areas of subspecialty include shoulder and knee ligament reconstruction, cartilage repair, concussion management, osteoporosis diagnosis and treatment, patellofemoral reconstruction and joint replacement.
This Circle is intended to evaluate the safety and efficacy of a single injection of autologous MiniTC MFAT for treatment of shoulder osteoarthritis with an additional diagnosis of partial thickness rotator cuff tear. Application of the MiniTC technology can aid in the production of a clinically relevant cell enriched autologous microfat grafts for use in the healing of degenerative joint diseases. Over an 2-year period, this Circle captures patient-reported data related to shoulder pain, function, and stiffness prior to and following a one-time treatment of MiniTC MFAT.
Interventional
- Longitudinal, real-world safety and efficacy assessment of MFAT.
- Collaboration with nationally recognized musculoskeletal physicians.
- Clinically significant registry datasets supporting standards of care for a variety of lower extremity pathologies.
- Visual Analogue Scale (VAS)
- Western Ontario Arthritis of the Shoulder Index (WOOS)
Related Posts
Use of a Autologous MiniTC MFAT Injection to Improve Shoulder Pain and Function Among Patients with Osteoarthritis
This Circle is intended to evaluate the safety and efficacy of a single injection of autologous MiniTC MFAT for treatment of shoulder osteoarthritis with an additional diagnosis of partial thickness rotator cuff tear. Application of the MiniTC technology can aid in the production of a clinically relevant cell enriched autologous microfat grafts for use in the healing of degenerative joint diseases. Over an 2-year period, this Circle captures patient-reported data related to shoulder pain, function, and stiffness prior to and following a one-time treatment of MiniTC MFAT.
VAS, WOOS
- Longitudinal, real-world safety and efficacy assessment of MFAT.
- Collaboration with nationally recognized musculoskeletal physicians.
- Clinically significant registry datasets supporting standards of care for a variety of lower extremity pathologies.
Streamlined patient enrollment, real-world data capturing, heightened recognition, prominence and collaboration
CIRCLE LIBRARY
CIRCLE NAME
Total Knee Arthroplasty Outcome-Based Performance Measure
SURVEYS
VAS
KOOS Jr.
VR-12 (compliant with CMS/IQR Requirements)
As specified by Provider
THIS CIRCLE IS FOR:
Provider Receiving CMS Reimbursement For TKAs
CMS will soon penalize providers performing total knee replacements which do not collect specified outcomes data from at least 50% of qualifying patients.
Other Providers Performing TKAs
Private insurance companies and other payers within and outside the U.S. will follow the CMS lead in requiring high patient compliance in reporting long-term TKA outcomes.
WHY CIRCLES
If you have any questions, please contact us.